Search

Your search keyword '"Gueth, Uwe"' showing total 39 results
Start Over Author "Gueth, Uwe"
39 results on '"Gueth, Uwe"'

21. Impact of hormone replacement therapy on the histologic subtype of breast cancer

Author

Zanetti-Dällenbach, Rosanna, Krause, Elke, Lapaire, Olav, Gueth, Uwe, Holzgreve, Wolfgang, Wight, Edward, Zanetti-Dällenbach, Rosanna, Krause, Elke, Lapaire, Olav, Gueth, Uwe, Holzgreve, Wolfgang, and Wight, Edward

Abstract

Objective: Postmenopausal hormone replacement therapy (HRT) is associated with an increase in breast cancer risk, which correlates to the duration of HRT use. We wanted to investigate a possible association between HRT use and the risk of a histologic subtype of breast cancer. Patients and methods: From 1995 until 2004, 497 cases of primary ductal, lobular or ductulolobular breast cancer in postmenopausal women were diagnosed at the Department of Gynecology and Obstetrics, University Hospital Basel, Switzerland. The data was derived from patient's records. HRT ever use was defined as HRT use for ≥6 months. Results: Of the 99 cases of lobular cancer 72.7% were invasive lobular cancers, 21.2% were invasive ductulolobular cancers and 6.1% were lobular cancers in situ. Of the 398 cases of ductal cancer, 90.5% were invasive ductal cancers and 9.5% were ductal cancers in situ. Totally 144 women were HRT ever users, and 341 women were HRT never users. HRT status could not be defined in 12 women. HRT ever use was associated with an increased risk for lobular cancer (OR 1.67; 95% CI 1.02-2.73). Also, menopause due to bilateral oophorectomy was associated with an increased risk for lobular cancer (OR 2.42; 95% CI 1.06-5.54). Conclusions: There is evidence that HRT as well as menopause due to bilateral oophorectomy may be associated with an increased risk for lobular cancer. This association is of major clinical relevance, since lobular breast cancer is more difficult to diagnose clinically and radiologically than ductal breast cancer

Published
2018

24. Preserving fertility in patients undergoing treatment for breast cancer: current perspectives

Author

Gueth, Uwe and Moffat,Rebecca

Subjects
Targets and Therapy [Breast Cancer]
Abstract

Rebecca Moffat,1 Uwe Güth2 1Women’s Hospital, Clinic for Gynecologic Endocrinology and Reproductive Medicine, University Hospital Basel, Basel, 2Department of Gynecology and Obstetrics, Breast Center, SenoSuisse, Cantonal Hospital Winterthur, Winterthur, Switzerland Abstract: Invasive breast cancer (BC) is the most frequent cancer of young women. Considering the trend toward postponing childbearing until the later reproductive years, the number of childless women at diagnosis of BC will continue to increase. The American Society of Clinical Oncology and the American Society for Reproductive Medicine have recommended that the impact of cancer treatments on fertility should be addressed with all cancer patients of reproductive age and that options for fertility preservation, such as cryopreservation of embryos and oocytes, ovarian tissue, in vitro maturation of immature oocytes, and ovarian suppression with gonadotropin-releasing hormone analogs, should be discussed routinely. To optimally counsel patients on how to best weigh the risks and benefits of fertility preservation, both the health care provider and the patient must know about the options, their risks, and their likelihood of success. The aim of this review is to summarize current knowledge on fertility preservation options for young BC patients, surrogates of ovarian function, psychosocial aspects of infertility after cancer treatment, women’s attitudes towards childbearing after cancer treatment, and health care providers’ attitudes towards fertility preservation. Keywords: breast cancer, fertility preservation, oncofertility, chemotherapy

Published
2014

38. Expression of peroxisome proliferator activated receptor and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

Author

Stadlmann, Sylvia, Gueth, Uwe, Wight, Edward, Kunz-Schughart, Leoni A., Hartmann, Arndt, and Singer, Gad

Subjects
*PEROXISOMES, *DRUG therapy, *TUMORS, *CANCER patients, *MICROBODIES
Abstract

Aim: Peroxisome proliferator-activated receptor γ (PPARγ) has emerged as a potential therapeutic target in several types of cancer. In ovarian carcinomas, limited and conflicting data on PPARγ protein expression have been reported. Methods: The immunoexpression of PPARγ and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy. Results: PPARγ expression was observed in 29% of primary and recurrent carcinomas. In the recurrent tumours, PPARγ expression inversely correlated with COX2 overexpression in both chemosensitive (p = 0.02) chemoresistent (p = 0.04) carcinomas. Conclusions: The data indicate that PPARγ may represent a potential target for second-line treatment in ovarian cancers. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

39. Impact of hormone replacement therapy on the histologic subtype of breast cancer

Author

Zanetti-Dällenbach, Rosanna, Krause, Elke, Lapaire, Olav, Gueth, Uwe, Holzgreve, Wolfgang, Wight, Edward, Zanetti-Dällenbach, Rosanna, Krause, Elke, Lapaire, Olav, Gueth, Uwe, Holzgreve, Wolfgang, and Wight, Edward

Abstract

Objective: Postmenopausal hormone replacement therapy (HRT) is associated with an increase in breast cancer risk, which correlates to the duration of HRT use. We wanted to investigate a possible association between HRT use and the risk of a histologic subtype of breast cancer. Patients and methods: From 1995 until 2004, 497 cases of primary ductal, lobular or ductulolobular breast cancer in postmenopausal women were diagnosed at the Department of Gynecology and Obstetrics, University Hospital Basel, Switzerland. The data was derived from patient's records. HRT ever use was defined as HRT use for ≥6 months. Results: Of the 99 cases of lobular cancer 72.7% were invasive lobular cancers, 21.2% were invasive ductulolobular cancers and 6.1% were lobular cancers in situ. Of the 398 cases of ductal cancer, 90.5% were invasive ductal cancers and 9.5% were ductal cancers in situ. Totally 144 women were HRT ever users, and 341 women were HRT never users. HRT status could not be defined in 12 women. HRT ever use was associated with an increased risk for lobular cancer (OR 1.67; 95% CI 1.02-2.73). Also, menopause due to bilateral oophorectomy was associated with an increased risk for lobular cancer (OR 2.42; 95% CI 1.06-5.54). Conclusions: There is evidence that HRT as well as menopause due to bilateral oophorectomy may be associated with an increased risk for lobular cancer. This association is of major clinical relevance, since lobular breast cancer is more difficult to diagnose clinically and radiologically than ductal breast cancer

Catalog

Books, media, physical & digital resources
See catalog results